# Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus

> **NCT02880852** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Belimumab

## Key facts

- **NCT ID:** NCT02880852
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-23
- **Primary completion:** 2017-09-08
- **Final completion:** 2017-09-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02880852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02880852, "Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02880852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*